This is correlated with the overexpression of an oncomiR, miR-155, which targets a partially conserved site in the 3′UTR of TRF1. Overexpression of miR-155 has been reported in over 80% of breast cancers that were classified with TRF1 downregulation [161]. The gene discussed is TERF1; the disease is breast cancer.